D
Dan McDonald
Researcher at Bristol-Myers Squibb
Publications - 13
Citations - 11213
Dan McDonald is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Monoclonal antibody. The author has an hindex of 10, co-authored 12 publications receiving 9903 citations.
Papers
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott,Charles G. Drake,Mario Sznol,Toni K. Choueiri,John D. Powderly,David Smith,Julie R. Brahmer,Richard D. Carvajal,Hans J. Hammers,I. Puzanov,F. Stephen Hodi,Harriet M. Kluger,Suzanne L. Topalian,Drew M. Pardoll,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Dan McDonald,Vindira Sankar,Jeffrey A. Sosman,Michael B. Atkins +20 more
TL;DR: Patients with advanced treatment-refractory RCC treated with nivolumab demonstrated durable responses that in some responders persisted after drug discontinuation, overall survival is encouraging, and toxicities were generally manageable.
Journal ArticleDOI
Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).
Julie R. Brahmer,Leora Horn,Scott J. Antonia,David R. Spigel,Leena Gandhi,Lecia V. Sequist,Jon M. Wigginton,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Scott N. Gettinger +10 more
TL;DR: It is reported here that BMS-936558 mediates antitumor activity in heavily pretreated patients with advanced NSCLC, a tumor historically not considered to be responsive to immunotherapy.
Journal ArticleDOI
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
F. Stephen Hodi,Mario Sznol,David F. McDermott,Richard D. Carvajal,Donald P. Lawrence,Suzanne L. Topalian,Jon M. Wigginton,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jeffrey A. Sosman +10 more
TL;DR: The activity and safety of BMS-936558 in patients (pts) with previously treated advanced MEL and underscores the importance of the PD-1/PD-L1 pathway in MEL therapy.
Journal ArticleDOI
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.
Rachel E. Sanborn,William H. Sharfman,Neil H. Segal,F. Stephen Hodi,Jedd D. Wolchok,Walter J. Urba,Bernard A. Fox,Suzanne L. Topalian,Drew M. Pardoll,Kelly L. Covello,Dan McDonald,Su Young Kim,Ashok Kumar Gupta,Jon M. Wigginton,Thomas F. Gajewski +14 more
TL;DR: A phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON).